Rifampicin Production Cost Analysis 2020
Rifampicin, which is also known as rifampin, is an antibiotic that is uitlised to treat numerous kinds of bacterial infections, like tuberculosis, mycobacterium avium complex, leprosy, and legionnaires’ disease. Rifampicin is created by the soil bacterium Amycolatopsis rifamycin. It is almost always used along with other antibiotics, except while it is given to prevent Haemophilus influenzae type B or meningococcal disease in people who have been exposed to those bacteria. Rifampicin may be given either orally or intravenously.
Rifampicin belongs to the rifamycin group of antibiotics. It works by blocking the production of RNA by bacteria. It was discovered in 1965, marketed in Italy in 1968, and finally approved in the United States in 1971. It is on the WHO’s List of Essential Medicines, which are the safest, as well as the most effective medicines required in a healthcare system. It is available as a generic medication.
Procurement Resource provides an in-depth cost analysis of Rifampicin production. The report incorporates the manufacturing process with detailed process and material flow, capital investment, operating costs along with financial expenses and depreciation charges. The study is based on the latest prices and other economic data available. We also offer additional analysis of the report with detailed breakdown of all cost components (Capital Investment Details, Production Cost Details, Economics for another Plant Location, Dynamic Cost Model).